Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/259592 http://scihub22266oqcxt.onion/10.1155/2015/259592 C4385644!4385644!25874129     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Nephrol 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=25874129|t=2015. Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial |pdf=|usr=}}{{25874129}} gab.com Text Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial JO: Int J Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=25874129 #FOAvip Background. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. Human studies have proved its antiproteinuric effect in patients with glomerular diseases, but this study was designed to assess the effects of add-on pentoxifylline to available treatment on reduction of microalbuminuria in diabetic patients without glomerular diseases. Methods. In a double-blind placebo-controlled, randomized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients. 40 diabetic patients with estimated glomerular filtration rate (eGFR) of more than 60?mL/min/1.73?m2 in eight weeks and microalbuminuria were randomized to two groups which will receive pentoxifylline 1200?mg/day or placebo added to regular medications for 6 months. albuminuria; eGFR was evaluated at three- and six-month follow-up period. Results. Baseline characteristics were similar between the two groups. At six months, the mean estimated GFR and albuminuria were not different between two groups at 3- and 6-month follow-up. Trend of albumin to creatinine ratio, systolic and diastolic blood pressure, and eGFR in both groups were decreased, but no significant differences were noted between two groups (P value > 0.05). Conclusion. Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease; however, further clinical investigations are necessary to be done. Twit Text FOAVip Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial ????Int J Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=25874129 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25874129 #FOAvip English Wikipedia <ref>{{Cite pmid|25874129}}</ref> Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial #MMPMID25874129 Shahidi S; Hoseinbalam M; Iraj B; Akbari M Int J Nephrol 2015[]; 2015 (ä): ä PMID25874129show ga Background. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. Human studies have proved its antiproteinuric effect in patients with glomerular diseases, but this study was designed to assess the effects of add-on pentoxifylline to available treatment on reduction of microalbuminuria in diabetic patients without glomerular diseases. Methods. In a double-blind placebo-controlled, randomized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients. 40 diabetic patients with estimated glomerular filtration rate (eGFR) of more than 60?mL/min/1.73?m2 in eight weeks and microalbuminuria were randomized to two groups which will receive pentoxifylline 1200?mg/day or placebo added to regular medications for 6 months. albuminuria; eGFR was evaluated at three- and six-month follow-up period. Results. Baseline characteristics were similar between the two groups. At six months, the mean estimated GFR and albuminuria were not different between two groups at 3- and 6-month follow-up. Trend of albumin to creatinine ratio, systolic and diastolic blood pressure, and eGFR in both groups were decreased, but no significant differences were noted between two groups (P value > 0.05). Conclusion. Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease; however, further clinical investigations are necessary to be done. äEffect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A R(epmc).pdf DeepDyve Pubget Overpricing